570 followers
Pooled Analysis of 8 Phase II/III Studies: The most commonly reported AEs (>10%) in the overall cariprazine-treatment group were akathisia (14.6%), insomnia (14.0%), and headache (12.1%). Other AEs: EPS (7.0%), sedation (3.7%), and somnolence (3.1%) htt